Testing Results of the BioOdyssey Calligrapher MiniArrayer for Clinical Research Available
News Nov 08, 2007
Bio-Rad Laboratories, Inc. has announced the availability of a technical bulletin (bulletin 5534A), that describes results of the testing of the BioOdyssey™ Calligrapher™ MiniArrayer, which is used for the printing of protein microarrays.
The widespread application of microarray technology to clinical research and clinical trials requires the ability to assess the technical and quality aspects of robotic devices that are used to construct the arrays.
Instruments approved for use in human clinical diagnostic laboratories must undergo extensive quality assessments, including documentation of accuracy, precision, linearity, and sensitivity for a given assay. As in a clinical setting, it is necessary to understand the capabilities and limitations of a robotic microarray printing device.
Bio-Rad’s bulletin 5534A provides an analysis of the issues associated with microarray printing and offers testing results of the BioOdyssey Calligrapher MiniArrayer that can be used to assess microarray printing results.
Along with a detailed introduction, the six-page bulletin uses diagrams, tables, and graphics to provide an extensive description of methods used in the evaluation.
Results of the evaluation confirm that the BioOdyssey Calligrapher MiniArrayer is technically capable to print reverse-phase microarrays (RPPAs) in batches up to 16 slides. Inter- and intra-slide CVs were <10% as evidenced through printing standard curves in replicates.
Genes Can Influence the Mutation, Activity of Nearby GenesNews
Study shows that a gene’s neighborhood can influence whether and how the activity of a gene changes.READ MORE
Brain Regions Implicated in Mental Disorders Influenced by Neanderthal GenesNews
Findings indicate that the more a person’s genome carries genetic vestiges of Neanderthals, the more certain parts of his or her brain and skull resemble those of humans’ evolutionary cousins that went extinct 40,000 years ago.READ MORE
Acquisition Sees Agilent Gain Powerful NGS IP PortfolioNews
Agilent Technologies announces its acquisition of the molecular and sample barcoding portfolios of Population Genetics Technologies.READ MORE
Comments | 0 ADD COMMENT
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018